TY - JOUR
T1 - The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the definition of improvement
AU - Ruperto, Nicolino
AU - Ravelli, Angelo
AU - Oliveira, Sheila
AU - Alessio, Maria
AU - Mihaylova, Dimitrina
AU - Pasic, Srdjan
AU - Cortis, Elisabetta
AU - Apaz, Maria
AU - Burgos-Vargas, Ruben
AU - Kanakoudi-Tsakalidou, Florence
AU - Norambuena, Ximena
AU - Corona, Fabrizia
AU - Gerloni, Valeria
AU - Hagelberg, Stefan
AU - Aggarwal, Amita
AU - Dolezalova, Pavla
AU - Saad, Claudia Magalhaes
AU - Bae, Sang-Cheol
AU - Vesely, Richard
AU - Avcin, Tadej
AU - Foster, Helen
AU - Duarte, Carolina
AU - Herlin, Troels
AU - Horneff, Gerd
AU - Lepore, Loredana
AU - van Rossum, Marion
AU - Trail, Lucia
AU - Pistorio, Angela
AU - Andersson-Gäre, Boel
AU - Giannini, Edward H.
AU - Martini, Alberto
PY - 2006
Y1 - 2006
N2 - To use the Pediatric Rheumatology International Trials Organization (PRINTO) core set of outcome measures to develop a validated definition of improvement for the evaluation of response to therapy in juvenile systemic lupus erythematosus (SLE). Thirty-seven experienced pediatric rheumatologists from 27 countries, each of whom had specific experience in the assessment of juvenile SLE patients, achieved consensus on 128 patient profiles as being clinically improved or not improved. Using the physicians' consensus ratings as the gold standard measure, the chi-square, sensitivity, specificity, false-positive and false-negative rates, area under the receiver operating characteristic curve, and kappa level of agreement for 597 candidate definitions of improvement were calculated. Only definitions with a kappa value greater than 0.7 were retained. The top definitions were selected based on the product of the content validity score multiplied by its kappa statistic. The definition of improvement with the highest final score was at least 50% improvement from baseline in any 2 of the 5 core set measures, with no more than 1 of the remaining worsening by more than 30%. PRINTO proposes a valid and reproducible definition of improvement that reflects well the consensus rating of experienced clinicians and that incorporates clinically meaningful change in core set measures in a composite end point for the evaluation of global response to therapy in patients with juvenile SLE. The definition is now proposed for use in juvenile SLE clinical trials and may help physicians to decide whether a child with SLE responded adequately to therapy
AB - To use the Pediatric Rheumatology International Trials Organization (PRINTO) core set of outcome measures to develop a validated definition of improvement for the evaluation of response to therapy in juvenile systemic lupus erythematosus (SLE). Thirty-seven experienced pediatric rheumatologists from 27 countries, each of whom had specific experience in the assessment of juvenile SLE patients, achieved consensus on 128 patient profiles as being clinically improved or not improved. Using the physicians' consensus ratings as the gold standard measure, the chi-square, sensitivity, specificity, false-positive and false-negative rates, area under the receiver operating characteristic curve, and kappa level of agreement for 597 candidate definitions of improvement were calculated. Only definitions with a kappa value greater than 0.7 were retained. The top definitions were selected based on the product of the content validity score multiplied by its kappa statistic. The definition of improvement with the highest final score was at least 50% improvement from baseline in any 2 of the 5 core set measures, with no more than 1 of the remaining worsening by more than 30%. PRINTO proposes a valid and reproducible definition of improvement that reflects well the consensus rating of experienced clinicians and that incorporates clinically meaningful change in core set measures in a composite end point for the evaluation of global response to therapy in patients with juvenile SLE. The definition is now proposed for use in juvenile SLE clinical trials and may help physicians to decide whether a child with SLE responded adequately to therapy
U2 - https://doi.org/10.1002/art.22002
DO - https://doi.org/10.1002/art.22002
M3 - Article
C2 - 16739203
SN - 0004-3591
VL - 55
SP - 355
EP - 363
JO - Arthritis and rheumatism
JF - Arthritis and rheumatism
IS - 3
ER -